994
Index
Succinylcholine, 427
Sucralfate, 896, 901, 909
Sulfacetamide, 112, 958
Sulfadiazine, 112
Sulfamethoxazole, 112, 820
Sulfasalazine, 112
Sulfonamides, 91, 112–114
adverse effects, 113
care considerations, 113–114
contraindications and cautions, 112
drug–drug interactions, 113
pharmacokinetics, 112
therapeutic actions and indications, 112
Sulfonylureas, 573, 585–588
adverse effects, 588
contraindications and cautions, 588
drug–drug interactions, 588
first generation, 587
pharmacokinetics, 588
second generation, 587
therapeutic actions and indications,
587–588
Sulindac, 247
Sumatriptan, 398, 411, 412
Sunitinib, 219, 220, 221
Superinfections, 31, 35, 81, 87
Suppressor T cells, 236
Supraventricular arrhythmias, 648
Surfactant, 835, 837
Suxamethonium, 432, 434, 437–438
elderly persons, in, 440–441
Swallowing, 888, 891, 893
Sweet violet flowers, 967
Sympathetic nervous system, 444–449
adrenergic receptors, 448
adrenergic response, 447–449
alpha-receptors, 444, 448
beta-receptors, 444, 448
blockers, 675–676
noradrenaline release, 448
noradrenaline synthesis and storage,
447–448
structure and function, 445–446
termination of response, 449
Sympatholytic drugs, 469, 470
Sympathomimetics, 455, 864, 867,
871–873
adverse effects, 872
care considerations, 872–873
contraindications and cautions, 872
drug–drug interactions, 872
pharmacokinetics, 872
therapeutic actions and indications,
871–872
Synapse, 292, 295–296
Syncytia, 642, 643
Synergistic, 90, 93
Synthetic drug sources, 5
Systemic arterial pressure, 652
Systemic circulation, 649, 650
Systemic infections, 85
Systole, 642, 644
T
T cells, 229, 233, 234
suppressors, 263–266
Tachycardia, 696, 698
Tachypnoea, 681, 684
Tacrine, 490
Tacrolimus, 260, 263
Tadalafl, 635–637
Tamoxifen, 191, 212, 215–216
Tamsulosin, 475, 828, 829
Tapentadol, 402
Tarragon, 967
Tazarotene, 953
Tea tree oil, 967
Teicoplanin, 83
Telaprevir, 144, 145
Telbivudine, 144, 145
Telmisartan, 665, 669
Temazepam, 305, 306
Temozolomide, 195, 197
Temsirolimus, 220, 221
Tenecteplase, 757, 764
Teniposide, 209
Tenofovir, 136, 137, 138
Teratogenicity, 2, 6, 38–39
Terazosin, 475, 676, 828, 829
Terbinafine, 151–154, 157, 952
Terbutaline, 465, 867, 871–872
Teriparatide, 565, 566
Testes, 596, 601–602
hormones and, 514
Testosterone, 596, 601–603, 627, 629, 630
Tetanus, 274, 286
Tetanus immune globulin, 286
Tetanus toxoids, 279–280
Tetracyclines, 91, 114–115, 117–118
adverse effects, 115
care considerations, 117–118
contraindications and cautions,
114–115
drug–drug interactions, 115
drug–food interactions, 115
pharmacokinetics, 114
therapeutic actions and indications, 114
Thalidomide, 119
Theophylline, 866–869, 879
toxic reaction to, 869, 870–871
Therapeutic concentration, 16
Therapeutic Goods Administration
(TGA), 2, 5
drug evaluation, 5–8
reporting medication errors, 49–50
Therapeutic Guidelines
, 12
Therapeutic index, 19–20
Thiazide and thiazide-like diuretics, 658,
805, 807–809
adverse effects, 809
contraindications and cautions,
808–809
drug–drug interactions, 809
pharmacokinetics, 808
therapeutic actions and indications,
807–808
Thiazolidinediones, 573, 587, 588–589
Thioamides, 551, 552
adverse effects, 561
drug–drug interactions, 561
pharmacokinetics, 560
therapeutic actions and indications, 560
Thioguanine, 200, 202
Thiopentone, 416, 419, 420
Thiotepa, 195, 197
Threadworm infections, 180, 181
threadworms, 179
Thrombin, 753–755, 759–760, 766,
768–770
Thromboembolic disorders, 750,
754–755
Thrombolytic agents, 750, 751, 764–766
adverse effects, 765
care considerations, 765–766
contraindications and cautions, 765
drug–drug interactions, 765
pharmacokinetics, 765
therapeutic actions and indications,
764–765
Thyme, 967
Thymosin, 235
Thymus gland, 235
Thyroid and parathyroid agents, 551–570
adults, 554
children, 554
older adults, 554
parathyroid agents, 565–569
antihypercalcaemic agents, 566,
567–569
antihypocalcaemic agents, 565–567
parathyroid glands, 552, 562–565
control, 563
dysfunction, 563
hormones and, 514
hyperparathyroidism, 563
hypoparathyroidism, 563, 564
structure and function, 562–563
thyroid agents, 556–562
antithyroid agents, 557, 560–562
care considerations, 558, 561–562
thyroid hormones, 556–558
Thyroid gland, 552–556
control, 553
dysfunction, 553–556
hormones and, 514
hyperthyroidism, 555, 556
hypothyroidism, 554–556
structure and function, 552–553
Thyroid hormones, 552, 556–558
adverse effects, 557
care considerations, 558
contraindications and cautions,
556–557
drug–drug interactions, 557
pharmacokinetics, 556
therapeutic actions and indications, 556
Thyrotropin-releasing hormone (TRH),
522
Thyrotropin alfa, 526, 530
Thyroxine, 551, 552, 556–558
Tiagabine, 354, 365–368
Tiaprofenic acid, 247
Ticagrelor, 756, 758
Ticarcillin, 108, 109
Ticarcillin and clavulanic acid
(
Timentin),
93
Ticlopidine, 756, 758
Tigecycline, 114, 121
